Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine1[S]
Immunization with homologous malondialdehyde (MDA)-modified LDL (MDA-LDL) leads to atheroprotection in experimental models supporting the concept that a vaccine to oxidation-specific epitopes (OSEs) of oxidized LDL could limit atherogenesis. However, modification of human LDL with OSE to use as an i...
Main Authors: | Ayelet Gonen, Lotte F. Hansen, William W. Turner, Erica N. Montano, Xuchu Que, Apaїs Rafia, Meng-Yun Chou, Philipp Wiesner, Dimitrios Tsiantoulas, Maripat Corr, Michael S. VanNieuwenhze, Sotirios Tsimikas, Christoph J. Binder, Joseph L. Witztum, Karsten Hartvigsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-10-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520350173 |
Similar Items
-
Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging
by: Matthew C. Zimmerman, et al.
Published: (2017-10-01) -
Identification of New Markers of Alcohol-Derived DNA Damage in Humans
by: Valeria Guidolin, et al.
Published: (2021-02-01) -
Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
by: Kevin Yee-Bien Tse, et al.
Published: (2013-12-01) -
C-reactive protein is an atheroprotective molecule
by: Pathak, Asmita, et al.
Published: (2018) -
Functionality of C-Reactive Protein for Atheroprotection
by: Sanjay K. Singh, et al.
Published: (2019-07-01)